The characteristics of choriocapillaris flow void in the unilateral polypoidal choroidal vasculopathy fellow eyes

Huajui Wu, Yukinori Sugano, Kanako Itagaki, Akihito Kasai, Hiroaki Shintake & Tetsuju Sekiryu*

To evaluate the morphological characteristics of flow void (FV) in the fellow eyes of the unilateral polypoidal choroidal vasculopathy (PCV). Fifty PCV fellow eyes (PCVF) and 31 age-matched normal ocular circulation controls were recruited in this retrospective study. The number of FV was analyzed according to the size in a centered 5 × 5 mm swept source optical coherence tomography angiography scans. We used indocyanine green angiography images to determine whether choroidal vascular hyperpermeability (CVH) has occurred. For the PCVF, the prevalence rate of CVH was 70% (35 of 50). The number of FVs was significantly lower in 400–25,000 μm² (P = 0.005), 400–500 μm² (P = 0.001), 525–625 μm² (P = 0.001) and 650–750 μm² (P = 0.018), compared to the controls. And showed no difference in size from 775 to 1125 μm² between the two groups. The area under the receiver operating characteristic curve of PCVF with CVH and controls was 0.94 (95% CI 0.88–1.00) (P < 0.001). We found that the number of small FVs was significantly lower in the PCV fellow eyes than that in the eyes with control group.

Polypoidal choroidal vasculopathy (PCV) is a distinctive clinical entity that may cause choroidal neovascularization (CNV) in elderly people as proposed by Yannuzzi in 1990. PCV is usually diagnosed by indocyanine green angiography (ICGA) examination, which detects polypoidal lesions or by indirect ophthalmoscopy, which identifies orange nodules structures. The genetic predisposition may affect the pathophysiology of the PCV. The fellow eyes of the PCV may be exposed to the background factors. And the PCV unaffected fellow eyes sometimes show thick choroid features, despite unilateral cases. These facts suggest that pathognomonic changes may already begin in the fellow eyes of PCV. Analysis of PCV fellow eyes may provide a clue to elucidate the pathogenesis of PCV.

The choroidal vasculature of PCV shows distinctive changes such as enlargement of vessels in the Harlerr's layer or attenuation of small vessels in the Sattler's layer. The changes of the choriocapillaris (CC) in PCV would be expected. However, it has been reported that there was no difference in vascular parameters of the choroidal vasculature, including the CC between the pachychoroid eyes without disease and normal eyes in a study using optical coherence tomography angiography (OCTA). Other studies have found that the CC flow deficit of PCV fellow eyes decreased, but did not reach statistical difference compared to the age-matched control group. Since CC cannot be delineated directly with the current OCTA devices, careful consideration is required to reach a conclusion.

Swept-source optical coherence tomography angiography (SS-OCTA) is often used to evaluate CC 2D images, due to its high scanning speed for evaluation. Although it has a wide depth range, the lateral resolution is generally lower than the spectral-domain OCTA. For example, the lateral resolution of Plex Elite 9000 SS-OCTA (Carl Zeiss Meditec Inc, Dublin, California, USA), which was used in this research, was 20 μm. The diameter of normal CC (16–20 μm) is smaller than the instrument resolution. We could not see the CC structures directly on the SS-OCTA image. We used CC flow void (FV) as a substitution for the CC structure, which was defined as the part of the CC slab without blood flow signals that diameter was bigger than the resolution of the SS-OCTA instrument.

Blood flow congestion in the choroid was postulated in PCV. We assumed that two possible changes were caused by congestion. One was that the enlargement of the capillary diameter due to congestion resulting FV

Department of Ophthalmology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, Japan. Email: sekiryu@fmu.ac.jp
773 patients met the exclusion criteria 1–3 and has been excluded.

39 patients met the exclusion criterion 4 and has been excluded.

Fellow eyes of RVO
Age-matched control group: 31 patients

CVH[−]: 15 patients
CVH[+]: 35 patients

Inclusion criteria
Japanese patients with unilateral PCV

Exclusion criteria
1. Eyes with combined retinal diseases or intraocular diseases.
2. Patients with any systemic diseases or allergies to the ICGA dye.
3. Refractive error ≥ -6 diopters or axial length ≥ 27 mm.
4. Any observed drusen, retinal pigment epithelium abnormality, or segmentation errors on the B-scan of SS-OCT images.

Methods
Patients. This was a retrospective comparative study that was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Fukushima Medical University (No. 2020-091), the Institutional Review Board of Fukushima Medical University approved the waiver for individual informed consent for this analysis.

We reviewed the medical records of 862 Japanese patients who were diagnosed as having unilateral PCV between June 2017 and August 2020 at Fukushima Medical University Hospital, Fukushima, Japan.

The inclusion criterion was a diagnosis of unilateral PCV evaluated by three ophthalmologists based on the presence of branching vascular networks, polypoidal lesions, and dilated aneurysmal lesions on ICGA (TRC 50DX, Topcon, Tokyo, Japan) according to the published criteria. Thirty-one fellow eyes of patients diagnosed as having unilateral retinal vein occlusion (RVO) were selected as an age-matched control group. All RVO patients underwent fluorescein angiography (FA) for clinical evaluation, and were confirmed to have no abnormality; there was no evidence of retinal pathological change in any of the participants in either group.

The exclusion criteria for all eyes were as follows: (1) eyes with any combined retinal disease or intraocular disease, such as a macular hole, central serous chorioretinopathy, uveitis, or glaucoma; (2) patients with any systemic disease that affects CC circulation, such as hypertension, diabetes, gout, hypercholesterolemia, or neoplasm, or are allergic to the ICGA dye; (3) the refractive error is greater than − 6 diopters or the axial length is over 27 mm; (4) any observed drusen, retinal pigment epithelium abnormality, or segmentation errors on the B-scan of SS-OCT images.

In which 773 PCV patients met the exclusion criteria 1–3 and has been excluded. We then reviewed the SS-OCT images of the remaining 89 patients, 39 of whom met exclusion criterion 4, and were excluded.

All patients who did not meet the exclusion criteria were enrolled. Fifty fellow eyes of 50 patients were categorized in the PCV fellow eyes (PCVF) group. According to the results of the choroidal vascular hyperpermeability (CVH) status, the PCVF group was further divided into two groups: PCV fellow eyes with CVH (CVH[+]) and PCV fellow eyes without CVH (CVH[−]). Thirty-one patients who were diagnosed as having unilateral retinal vein occlusion (RVO) were selected as controls (Fig. 1).

Clinical examination. All enrolled patients underwent comprehensive ophthalmic examinations, including indirect ophthalmoscopy, slit-lamp biomicroscopy, color, and red-free fundus photography, SS-OCTA, and ICGA (PCVF)/or FA (control) at the first visit. RVO patients did not receive ICGA for ethical reasons.
The CVH was defined as hyper fluorescence seen in the mid-phase of the ICGA images (10 min after the dye was injected), and the correspondent area of the OCTA images (Fig. 2).

The CVH was evaluated by two masked ophthalmologists. The 5 min images were as the reference and scored the ICGA images around 10 min. The scores were defined as follows. All participants of the control group were scored 0. A score of 1 was given when there was no distinguishable CVH in the area (CVH[−]); and a score of 2 was given when there was obvious and strong CVH in the area (CVH[+]). When the results were inconsistent, another experienced ophthalmologist made the judgment.

The subfoveal choroidal thickness (SFCT) was measured by masked ophthalmologists as the vertical distance between the RPE and the choroidoscleral border at the center of the fovea on the B-scan of the SS-OCT, using ImageJ software, version 1.52p (National Institutes of Health, Bethesda, Maryland, USA. https://imagej.nih.gov/ij/index.html).

Imaging processing. To analyze the FV, we conducted the binarization of the CC slab and grouped the FV according to our previous research (Fig. 3).

We imported the CC slab bounded from 31 to 40 μm beneath the RPE reference and the correspondent en-face structural image to MATLAB R2019a. (The MathWorks Inc. Natick, Massachusetts, USA). A compensation algorithm was used to eliminate the influence of the shadowing effect on the angiography images. We then imported the compensated images into ImageJ and processed the "Phansalkar local threshold" (radius = 5) for binarization. After binarization, we processed "Analyze Particles" and "watershed irregular" to remove the signal noise.

Since the center of the macula of some subjects was displaced from the center of the image (~210 to 455 μm), we performed manual correction to ensure that all images contained the same 5 × 5 mm² area centered at the fovea. We applied "Analyze Particles" to summarize the FV in each interval.

Figure 2. Representative images of choroidal vascular hyperpermeability status grading. The square represents a 5 × 5 mm² area corresponding to the OCTA image. (A,C) ICGA images taken 5 min after the dye injection, as a benchmark for comparison. (B,D) ICGA images taken about 10 min after the dye injection, to evaluate the CVH status in the square. (B) Scored 1 (CVH[−]): compared with (A) has no choroidal vascular hyperpermeability. (D) Scored 2 (CVH[+]): compared with (C) has obvious and strong choroidal vascular hyperpermeability. CVH[−]: PCV fellow eyes without choroidal vascular hyperpermeability. CVH[+]: PCV fellow eyes with choroidal vascular hyperpermeability.
Statistical analysis. Statistical calculations were performed by IBM SPSS V.26 for Windows (IBM Co., Armonk, New York, USA). A P value of less than 0.05 was defined as statistically significant. The Kolmogorov–Smirnov test (K–S test) was performed to detect the normality of distribution. Because the K–S test of the FV number showed significance in most intervals, all variables are expressed as median and quartile deviation. The independent samples median test, adjusted by Bonferroni correction, was used to calculate the differences between the groups. Spearman’s rank correlation coefficient was performed to evaluate the correlation between FV and CVH. The Youden index was used to determine the best cut-off point for the receiver operating characteristic (ROC) curve between the CVH[+] group and the controls.

The size of FV analysis. We compared the number and distribution of FVs between the PCVF group and controls in the following intervals to confirm the difference between the fellow eyes of PCV and normal circulation eyes.

The primary outcome was the number of FVs in different intervals between PCVF group and controls.

The number of FVs was divided into the following seven groups.

FVall: the FV sizes ranged from 400 to 25,000 μm² (16–1000 pixels). FV500: the FV sizes ranged from 400 to 500 μm² (16–20 pixels). FV625: the FV sizes ranged from 525 to 625 μm² (21–25 pixels). FV750: the FV sizes ranged from 650 to 750 μm² (26–30 pixels). FV875: the FV sizes ranged from 775 to 875 μm² (31–35 pixels). FV1000: the FV sizes ranged from 900 to 1000 μm² (36–40 pixels). FV1125: the FV sizes ranged from 1025 to 1125 μm² (41–45 pixels).

We calculated the total area of the FV sizes ranged from 400 to 25,000 μm² for comparison (FVarea).

The relationship between CVH and FV. To investigate the relationship between FV and CVH status, we performed Spearman’s rank correlation analysis among the FV and CVH status in all intervals.

We then compared the number of FVs between CVH[+], CVH[−] and control groups in each interval to determine the influence of CVH.

ROC analysis. We used binary logistic regression analysis for the CVH[+] and control groups depending on the results of the FV and CVH analyses.

FV smaller than 750 μm² was grouped every 25 μm² (1 pixel) and subjected to a binary logistic regression analysis after standardization.

We performed ROC analysis to determine a cut-off value for maximizing sensitivity and specificity to discriminate between the two groups.
No. of eyes (No. of right eyes) | PCVF | Control | P value
--- | --- | --- | ---
50 (27) | 31 (14) | 0.103

| Groups  | PCVF | Control | P value |
|---------|------|---------|---------|
| No. of male | 40 (80.0%) | 21 (67.7%) | 0.105 |
| Age (years) | 68.4 ± 7.8 | 67.7 ± 8.8 | 0.671 |
| Re (Diopter) | 0.5 ± 1.8 | 0.3 ± 1.8 | 0.677 |
| SFCT (μm) | 241.3 ± 84.2 | 220.8 ± 55.9 | 0.234 |

Table 1. Characteristics of participant groups (mean ± SD). Re refractive error, SFCT subfoveal choroidal thickness, PCVF PCV fellow eyes, Control age-matched control group. *Student t-test.

**Results**

**Baseline characteristics.** The mean ages were 68.4 ± 7.8 (51–84 years) in the PCVF group and 67.7 ± 8.8 (55–84 years) in the control group. There were no differences observed between the two groups regarding gender (P = 0.105), age (P = 0.677), refractive error (P = 0.677), or subfoveal choroidal thickness (P = 0.234).

The prevalence rate of CVH was 70% in the PCVF group (35 of 50 participants.)

The demographic characteristics of the groups are shown in Table 1.

**Validation of the normal distribution.** The Kolmogorov–Smirnov test results between the two groups were as follow: age: P = 0.200; Refractive error: P = 0.200; SFCT: P = 0.200; FVall: P = 0.003; FV500: P < 0.001; FV625: P = 0.002; FV750: P = 0.023; FV875: P = 0.200; FV1000: P = 0.200; FV1125: P = 0.200; FVarea: P = 0.006.

**The number of FVs.** The relationship between FV size and FV number is presented in Fig. 4 and Table 2.

In a comparison between the PCVF and control groups, the number of FVs in the PCVF group at all intervals was lower than that in the control group. There was statistical significance between the PCVF and the control group in the following intervals: FVall (P = 0.005), FV500 (P = 0.001), FV625 (P = 0.001) and FV750 (P = 0.018). No difference was observed between the two groups in FV875 (P = 0.984), FV1000 (P = 0.930) or FV1125 (P = 0.984).

**The analysis between FV and CVH.** In a comparison among all participants, the number of FVs in the following intervals was significantly negative correlated with the CVH status: FVall (r = −0.39, P < 0.001), FV500 (r = −0.45, P < 0.001), FV625 (r = −0.36, P = 0.001) and FV750 (r = −0.30, P = 0.006) (Table 3).

In a comparison among the CVH[+], CVH[−] and control groups, the number of FVs was significantly lower in the CVH[+] group compared to the control group at the following intervals: FVall (P = 0.004), FV500 (P = 0.001), FV625 (P = 0.001) and FV750 (P = 0.020). No difference was observed among the groups in FV875 (P = 0.217), FV1000 (P = 0.513) or FV1125 (P = 0.522). There were no differences between the CVH[+] and CVH[−] groups, or between CVH[−] and control group at any interval (all P > 0.05) (Table 4).

**The ROC curve of the CVH[+] and control groups.** Based on the Youden index, the cut-off points of the FVs for predicting fellow eyes in PCV patients with CVH was 0.56, with a sensitivity of 91.4%, specificity of 86.0%, and an area under the curve (AUC) of 0.94 (95% CI 0.88–1.00) (P < 0.001) (Fig. 5).

**Discussion**

In our retrospective study, the number of FVs smaller than 750 μm² substantially decreased in the PCVF group compared to the control group; whereas, the total FV area did not differ between the two groups. Most of the PCVF showed CVH (70%; 35 of 50). The status of CVH negatively correlated to the number of FVs.

This is the first study to determine the difference between the fellow eyes of PCV and control eyes using a non-invasive, commercially available SS-OCTA instrument.

Previous studies of ICGA have shown that the pathological changes of PCV and central serous chorioretinopathy have a similar choroidal vascular circulatory disturbance. For the very early stage of the PCV which the choroid shows no pathological changes, recent researches cannot tell the difference. However, we found that FV had decreased in the fellow eyes of PCV compared to the controls.

There were different protocols of CC slab obtained by OCTA. We decided on a protocol that has been implemented in other studies as the standard of our research. We then used our previously published FV analysis method which involved grouping the FV by size and performing statistical analyses on each group.

Due to the power-law distribution (Fig. 6), there was a relatively larger number of smaller-sized FVs, whereas larger FVs were of a relatively smaller number. If a pathological change occurs in the smaller-sized FV, average-sized FVs may not be affected; on the other hand, if a pathological change occurs in the larger FVs, it was too scarce to affect the total number of FVs. Evaluating the number of grouped FV sizes has another advantage, in that drusen are relatively large in size and frequently appear in PCV. The drusen area can decrease the penetration of OCTA laser to underestimating the FV density. Our grouping strategy can reduce the influence of drusen by calculating the number of FVs rather than the FV area.

---

**Table 1.** Characteristics of participant groups (mean ± SD). Re refractive error, SFCT subfoveal choroidal thickness, PCVF PCV fellow eyes, Control age-matched control group. *Student t-test.
The upper limit of the interval in our study was 1125 μm². Due to the power-law distribution, an FV larger than 1125 μm² contained less than 5% of the total, which were excluded from the statistics. An FV smaller than 750 μm² in PCVF was lower in number compared to control group because a small FV is more sensitive to radius changes. For example, when the radius is reduced by 1 μm in two FVs with original areas of 20 μm² and 210 μm², the FV size in the latter one would be reduced by a larger percentage.

**Figure 4.** Comparison of FVs between PCV fellow eyes and controls. *P* value of independent-samples median test. The number of FVs was significantly lower in the PCVF group compared to the controls in FVall, FV500, FV625, and FV750. There were no differences between the two groups in FV875, FV1000, and FV1125. *P < 0.05, **P < 0.01. FV choriocapillaris flow void, Control control group, PCVF PCV fellow eyes, FVall FV sizes from 400 to 25,000 μm², FV500: FV sizes from 400 to 500 μm², FV625: FV sizes from 525 to 625 μm², FV750: FV sizes from 650 to 750 μm², FV875: FV sizes from 775 to 875 μm², FV1000: FV sizes from 900 to 1000 μm², FV1125: FV sizes from 1025 to 1125 μm².

**Table 2.** The number of the flow void in different sizes. QD quartile deviation, Control age-matched control group, PCVF PCV fellow eyes. *Independent-samples median test. *P < 0.05, **P < 0.01.
Table 3. The correlation between choroid vascular hyperpermeability and flow void. FV choriocapillaris flow void. † Spearman’s rank correlation coefficient. **P < 0.01.

| Intervals of FV sizes | r    | P value† |
|-----------------------|------|----------|
| FVall (0–25,000 μm²)  | −0.39| <0.001** |
| FV500 (400–500 μm²)   | −0.45| <0.001** |
| FV625 (525–625 μm²)   | −0.36| 0.001**  |
| FV750 (650–750 μm²)   | −0.30| 0.006**  |
| FV875 (775–875 μm²)   | −0.14| 0.227    |
| FV1000 (900–1000 μm²) | −0.07| 0.531    |
| FV1125 (1025–1125 μm²)| 0.004| 0.973    |

Table 4. The number of the flow void in different CVH status. QD quartile deviation, FV choriocapillaris flow void, Control age-matched control group, CVH[−] PCV fellow eyes without choroidal vascular hyperpermeability, CVH[+] PCV fellow eyes with choroidal vascular hyperpermeability. Independent-Samples Median Test, adjusted by the Bonferroni correction. *P < 0.05, **P < 0.01.

| Intervals of FV sizes | Control (n = 31) (median, QD) | CVH[−] (n = 15) (median, QD) | CVH[+] (n = 35) (median, QD) | P value Control vs CVH[−] | P value CVH[−] vs CVH[+] | P value Control vs CVH[+] |
|-----------------------|--------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|---------------------------|
| FVall (0–25,000 μm²)  | 9297.0, 2063.0                  | 8525.0, 1968.0                | 8240.0, 1043.0                | P = 1.000                 | P = 1.000                 | P = 0.004**               |
| FV500 (400–500 μm²)   | 4153.0, 1455.0                  | 3015.0, 1240.0                | 2851.0, 274.0                 | P = 0.083                 | P = 1.000                 | P = 0.001**               |
| FV625 (525–625 μm²)   | 1704.0, 335.0                   | 1518.0, 285.0                 | 1442.0, 153.0                 | P = 0.347                 | P = 1.000                 | P = 0.001**               |
| FV750 (650–750 μm²)   | 1170.0, 224.0                   | 1064.0, 250.0                 | 1050.0, 155.0                 | P = 0.347                 | P = 1.000                 | P = 0.020*                |
| FV875 (775–875 μm²)   | 768.0, 134.0                    | 793.0, 97.0                   | 769.0, 116.0                  | P = 0.217                 | P = 0.217                 | P = 0.217                 |
| FV1000 (900–1000 μm²) | 551.0, 119.0                    | 563.0, 86.0                   | 537.0, 109.0                  | P = 0.513                 | P = 0.513                 | P = 0.513                 |
| FV1125 (1025–1125 μm²)| 372.0, 126.0                    | 391.0, 60.0                   | 369.0, 110.0                  | P = 0.522                 | P = 0.522                 | P = 0.522                 |

Figure 5. The receiver operating characteristic curve of the fellow eyes of PCV with choroidal vascular hyperpermeability and controls. The circled point is the best cut-off point. Youden index = 0.56, sensitivity = 91.4%, specificity = 86.0%. The area under the curve (AUC) = 0.94 (95% CI 0.88–1.00) (P < 0.001).
The decreasing size of the FV represents an increase in the blood flow signal area, which might be due to the hyperpermeability of CC, an increase of vessel diameter, or an increase in blood flow.

Recently, OCTA has been effectively detect typical pathological manifestations of PCV. Luo et al. reported similar results to ours in that the proportion of the choriocapillaris flow deficit area of PCV fellow eyes has a decreasing trend, but there was no statistical difference compared with an age-matched control group. However, in the present research, the number of FVs in small sizes was lower compared to that of the controls, while the total area had no difference.

We believe that the insignificant difference in FV in Luo’s research was due to the proportion area analysis strategy or the impact of underlying diseases, which may have resulted in an overall decrease in trend but was not statistically significant. Choroidal circulation can change due to many systemic and ocular factors, such as age, choroidal thickness, intraocular pressure, and systemic diseases. These factors may also change the morphology of the CC, resulting in FV changes. The previous research also revealed that the size of FV in diabetic retinopathy eyes is larger than that in control elderly eyes, and this trend positively correlated with the severity of diabetic retinopathy. Hypertension can also increase the size and number of FVs. Eyes with advanced Age-Related Eye Disease Study Category stage (AREDS stage) will cause an increase in the size and number of FVs. We excluded subjects who had suspected drusen or RPE abnormality on the B-scan, or diseases that had an impact on the CC structure. It can be considered that the different number of FV was not due to from age or any other systematic diseases.

Previous histopathological studies have reported that the CC of the eyes with advanced PCV can have plumped endothelial cells, primitive or narrow lumen, or dilated vessels. Our results showed that the reduction of the CVH status negatively correlated with number of FVs. However, the number of FVs of CVH− was between the number of those of CVH+ and the control group, and showed no significant difference (Table 4).

There are three possibilities. (1) those in the CVH− group are at an earlier stage of PCV than those in the CVH+ group, and the severity of CVH does not reach an observable level. (2) Although most of the fellow eyes of PCV tend to develop into PCV in the future, not all do. The CVH− are normal eyes at the beginning and will not develop into PCV. (3) The number of CVH− eyes was too low to achieve significance.

CVH is more commonly seen in eyes with pachychoroid, but it also occurred in few PCV and fellow eyes. A previous study of CVH using monkeys and rabbits had proved that the dye of ICGA was exuded and the CVH was formed due to vascular endothelial damage, suggesting that CVH exhibits vessel abnormalities at the innermost choroid. Based on the mechanism of OCTA, the blood flow signals came from the movement of red blood cells, and the decrease of the area without blood flow signals (FV) means that the area occupied by red blood cells increased. However, red blood cells should not exist outside the vessels. In other words, the diameter of the CC that parallel to the RPE was increased (Fig. 7).

One possibility is that due to the vasodilation of the choroidal vessels, the CC was squeezed toward the RPE, causing mechanical deformation of the CC (the diameter of the CC perpendicular to the RPE decreased and the diameter parallel to the RPE increased). As the CC lumen is squeezed, local blood flow can be slowed down and occurred turbulence. Slow blood flow and turbulence cause thrombosis and may be further related to the pathogenesis of PCV (Fig. 7G). Another possibility is that the diameters perpendicular to the RPE and parallel to the RPE were both dilated, induced CC endothelial damage, which causes the leakage of ICGA dye, and exhibited CC hyperpermeability. At the same time, due to endothelial damage, the concentration of vascular endothelial growth factors increased. Which in turn further promoted vasodilation and eventually formed pachychoroid disease (Fig. 7H).
These two assumptions have the same characteristics on the CC slab of SS-OCTA: the diameter parallel to the CC slab increased, and the FV became smaller (Fig. 7C,D).

Our result shows that the hyperpermeability of PCVF occurs earlier than detectable RPE abnormalities on B-scans of SS-OCT.

Based on the Youden index, our model has high sensitivity (91.4%) and specificity (86.0%). There is currently no method to detect specific signs before the first eye of PCV onset. Our model shows a reliable prediction (AUC = 0.94) of PCV using non-invasive, dye-free and commercially available OCTA instruments. Therefore, this model, with the number of FVs as a predictor, is helpful. The change of FVs can give a clue for the early screening of PCV in the future.

The limitations of present study are its retrospective nature and small sample size. Although we strictly controlled the underlying conditions of both groups, fellow eyes of RVO may have had some unknown conditions that could have limited the generalizability of our findings in clinical practice. We used the watershed method to separate the large FVs, which may lead to underestimation of the number of large FVs and overestimation of the number of the small FVs. Moreover, CVH can also occur in other diseases, including central serous chorioretinopathy. Further research is necessary to specifically distinguish PCV with CVH from other diseases.

In conclusion, the number of FV was significantly lower in fellow eyes of PCV than in eyes with normal ocular blood circulation. In most of the PCV fellow eyes of this research, CVH occurred, which should be the earliest detectable sign of PCV when investigations yield normal results.

Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 19 May 2021; Accepted: 8 November 2021
Published online: 29 November 2021

References
1. Yannuzzi, L. A., Sorenson, J., Spaide, R. F. & Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10, 1–8 (1990).
2. Spaide, R. F., Yannuzzi, L. A., Slakter, J. S., Sorenson, J. & Orlach, D. A. Indocyanine green videoangiography of idiopathic poly-poidal choroidal vasculopathy. Retina 15, 100–110 (1995).
3. Sho, K. et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch. Ophthalmol. 121, 1392–1396 (2003).
4. Spaide, R. F. & Ledesma-Gil, G. Choriocapillaris vascular parameters in normal eyes and those with pachychoroid with and without disease. Retina 20, 20 (2020).
5. Luo, M. et al. Comparison of choriocapillaris flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. BMC Ophthalmol. 20, 162 (2020).
6. Kashani, A. H. et al. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications. *Prog. Retin Eye Res.* 60, 66–100 (2017).

7. Olver, J. M. Functional anatomy of the choroidal circulation: Methyl methacrylate casting of human choroid. *Eye (Lond.)* 4(Pt 2), 262–272 (1990).

8. Yoneya, S. & Tso, M. O. Angiographic architecture of the human choroid. *Arch. Ophthalmol.* 105, 681–687 (1987).

9. Fryczkowski, A. W. Anatomical and functional choroidal lobuli. *Int. Ophthalmol.* 18, 131–141 (1994).

10. Schindel, I. J. et al. Fiji: An open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682 (2012).

11. Huajui, Wu. *et al.* A modified measuring method to investigate the choriocapillaris flow void of polypoidal choroidal vasculopathy with swept source optical coherence tomography angiography. *Quant. Imaging Med. Surg.* 11(7), 3146–3156 (2021).

12. Spade, R. F., Fujimoto, J. G. & Waheed, N. K. Image artifacts in Optical coherence tomography angiography. *Retina* 35, 2163–2180 (2015).

13. Zhang, A., Zhang, Q. & Wang, R. K. Minimizing projection artifacts for accurate presentation of choroidal neovascularization in OCT micro-angiography. *Biomed. Opt. Express* 6, 4130–4143 (2015).

14. Neerad, P., Sumit, M., Ashish, S. & Madhuri, I. Adaptive local thresholding for detection of nuclei in diversity stained cytology images. In 2011 International Conference on Communications and Signal Processing 218–220 (2011).

15. Soille, P. & Vincent, L. *Determining Watersheds in Digital Pictures Via Flooding Simulations* (SPIE, 1990).

16. Guyer, D. R. *et al.* Digital indocyanine-green videoangiography of occult choroidal neovascularization. *Ophthalmology* 101, 1727–1735 (1994).

17. Baek, J., Cheung, C. M. G., Jeon, S., Lee, J. H. & Lee, W. K. Polypoidal Choroidal vasculopathy: Outer retinal and choroidal changes and neovascularization development in the fellow eye. *Invest. Ophthalmol. Vis. Sci.* 60, 590–598 (2019).

18. Chu, Z., Gregori, G., Rosenfeld, P. J. & Wang, R. K. Quantification of choriocapillaris with optical coherence tomography angiography: A comparison study. *Am. J. Ophthalmol.* 208, 111–123 (2019).

19. Byon, I., Nassimi, M., Borrelli, E. & Sadda, S. R. Impact of slab selection on quantification of choriocapillaris flow deficits by optical coherence tomography angiography. *Am. J. Ophthalmol.* 208, 397–405 (2019).

20. Chu, Z. *et al.* Quantification of choriocapillaris with phansalkar local thresholding: Pitfalls to avoid. *Am. J. Ophthalmol.* 213, 161–176 (2020).

21. Chu, Z., Zhang, Q., Gregori, G., Rosenfeld, P. J. & Wang, R. K. Guidelines for Imaging the choriocapillaris using OCT angiography. *Am. J. Ophthalmol.* 222, 92–101 (2020).

22. Newman, M. E. J. *Power laws, Pareto distributions and Zipf’s law.* Contemp. Phys. 46, 323–351 (2005).

23. Spade, R. F. Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. *Retina* 38, 708–716 (2018).

24. Spade, R. F. Choriocapillaris flow features follow a power law distribution: Implications for characterization and mechanisms of disease progression. *Am. J. Ophthalmol.* 170, 58–67 (2016).

25. Kim, K. *et al.* A comparison study of polypoidal choroidal vasculopathy imaged with indocyanine green angiography and swept source OCT angiography. *Am. J. Ophthalmol.* 20, 20 (2020).

26. Yun, C., Nam, K. T., Park, S., Hwang, S. Y. & Oh, J. Features of the choriocapillaris on four different optical coherence tomography angiography devices. *Int. Ophthalmol.* 40, 325–333 (2020).

27. Zheng, F. *et al.* Age-dependent changes in the macular choriocapillaris of normal eyes imaged with swept-source optical coherence tomography angiography. *Am. J. Ophthalmol.* 200, 110–122 (2019).

28. Sacconi, R. *et al.* Quantitative changes in the ageing choriocapillaris as measured by swept source optical coherence tomography angiography. *Br. J. Ophthalmol.* 103, 1320–1326 (2019).

29. Rochepeau, C. *et al.* Optical coherence tomography angiography quantitative assessment of choriocapillaris blood flow in central serous chorioretinopathy. *Am. J. Ophthalmol.* 194, 26–34 (2018).

30. Mammo, Z. *et al.* Quantitative optical coherence tomography angiography of radial peripapillary capillaries in glaucoma, glaucoma suspect, and normal eyes. *Am. J. Ophthalmol.* 170, 41–49 (2016).

31. Yarmohammadi, A. *et al.* Optical coherence tomography angiography vessel density in healthy, glaucoma suspect, and glaucoma eyes. *Invest. Ophthalmol. Vis. Sci.* 57, 451–459 (2016).

32. Thompson, I. A., Durrani, A. K. & Patel, S. Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy. *Eye (Lond.)* 33, 648–652 (2019).

33. Cao, D. *et al.* Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. *Acta Diabetol.* 55, 469–477 (2018).

34. Dodoo, Y. *et al.* Clinical relevance of reduced decorrelation signals in the diabetic inner choroid on optical coherence tomography angiography. *Sci. Rep.* 7, 5227 (2017).

35. Bosch, A. J. *et al.* Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. *BMC Cardiovasc. Disord.* 17, 300 (2017).

36. Sun, C. *et al.* Systemic hypertension associated retinal microvascular changes can be detected with optical coherence tomography angiography. *Sci. Rep.* 10, 9580 (2020).

37. Junar, A. *et al.* Improvement in retinal capillary rarefaction after valsartan treatment in hypertensive patients. *J. Clin. Hypertens. (Greenwich)* 18, 1112–1118 (2016).

38. Mullins, R. F., Johnson, M. N., Faidley, E. A., Skeie, J. M. & Huang, J. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. *Invest. Ophthalmol. Vis. Sci.* 52, 1606–1612 (2011).

39. Biesemeier, A., Taubitz, T., Juliens, S., Voeruek, E. & Schaertrameyer, U. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. *Neurobiol. Aging* 55, 2562–2573 (2014).

40. Okubo, A., Sameshima, M., Uemura, A., Kanda, S. & Ohba, N. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. *Br. J. Ophthalmol.* 86, 1093–1098 (2002).

41. Lafaut, B. A., Aisenbrey, S., Van den Broecke, C., Bartz-Schmidt, K. U. & Heimann, K. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: A clinicopathologic correlation. *Retina* 20, 650–654 (2000).

42. Moussa, K. *et al.* Polypoidal choroidal vasculopathy: A clinicopathologic study. *Retin. Cases Brief Rep.* 11(Suppl 1), S128–S131 (2017).

43. Borooah, S. *et al.* Pachychoroid spectrum disease. *Acta Ophthalmol.* 20, 20 (2020).

44. Yanagi, Y. *et al.* Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. *Retina* 38, 1509–1517 (2018).

45. Lee, J. & Byeon, S. H. Prevalence and clinical characteristics of pachydrusen in polypoidal choroidal vasculopathy: Multimodal image study. *Retina* 39, 670–678 (2019).

46. Koizumi, H., Yamagishi, T., Yamazaki, T. & Kinoshita, S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. *Am. J. Ophthalmol.* 155, 305–313 e301 (2013).

47. Chung, S. E., Kang, S. W., Kim, J. H., Kim, Y. T. & Park, D. Y. Engagement of vortex vein and polypoidal choroidal vasculopathy. *Invest. Ophthalmol. Vis. Sci.* 53, 834–840 (2013).

48. Ryu, G., Moon, C., van Hemert, J. & Saengq, M. Quantitative analysis of choroidal vasculature in polypoidal choroidal vasculopathy using ultra-widefield indocyanine green angiography. *Sci. Rep.* 10, 18272 (2020).
49. Sasahara, M. et al. Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am. J. Ophthalmol. 142, 601–607 (2006).

50. Yoshioka, H. The etiology of central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 95, 1181–1195 (1991).

Author contributions
H.W. and T.S. designed the study. T.S. wrote the application to the ethics committee. T.S., Y.S., and A.K. performed the ophthalmological examinations. H.W., K.I., and H.S. reviewed the medical records and OCTA images and collected all imaging data. H.W., A.K., and T.S. evaluated CVH status. K.I. and H.S. evaluated SFCT in all images. H.W. and Y.S. performed statistical analyses. All authors wrote and reviewed the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021